FDA Launches ALS Gait Measurement Project
The initiative at Massachusetts General Hospital aims to validate digital mobility tracking for clinical drug trials.
Updated on Oct. 30, 2026 in Stroke
Live Poll
Do you believe using digital wearable sensors in medical trials will improve patient health outcomes?
The FDA has launched a new clinical trial readiness project at Massachusetts General Hospital to validate gait velocity measurements for patients with Amyotrophic Lateral Sclerosis. This effort seeks to standardize digital mobility data for use in drug development.
Why it matters
By establishing reliable digital biomarkers, researchers aim to improve the accuracy of measuring treatment effects in ALS. The initiative intends to support the integration of these measures as secondary or exploratory endpoints in future clinical trials.
The project centers on the 95th centile of stride velocity measured via wearable sensors. This data is being compared against traditional ALS outcome measures and patient usability reports.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
Massachusetts General Hospital
This academic medical center serves as the primary clinical site for the new ALS digital health demonstration project.
The details
Researchers are evaluating how digital mobility measures correlate with established clinical milestones and patient-reported changes in mobility. The project focuses on confirming the usability of wearable sensors to capture consistent data during pharmaceutical testing.
Timeline
October 30, 2026: The project was officially announced.
The Big Picture
This study follows the protocols established by the FDA digital health technologies in drug development demonstration projects. It marks a shift toward integrating continuous digital mobility data into clinical trial frameworks for neurodegenerative diseases.
This project could eventually lead to more precise and less intrusive monitoring for ALS patients participating in clinical research. By validating these digital tools, the FDA may shorten the time required to evaluate new drug efficacy in future studies.
The takeaway
Validating digital sensors offers a scalable way to monitor patient mobility in real time during drug trials. Researchers hope that these metrics will provide a clearer picture of how specific medications impact the daily lives of ALS patients.
Further reading
Learn more about the latest advancements in tracking neurological conditions in the United States Stroke section.
More information
Review the full FDA digital health demonstration projects list to understand the scope of the program.
Source note: This article includes information reported by U.S. Food and Drug Administration.
Live Poll
Do you believe using digital wearable sensors in medical trials will improve patient health outcomes?
